Compare DOGZ & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DOGZ | TOVX |
|---|---|---|
| Founded | 2003 | 2001 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Miscellaneous manufacturing industries | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.6M | 11.1M |
| IPO Year | 2017 | 2012 |
| Metric | DOGZ | TOVX |
|---|---|---|
| Price | $0.46 | $0.16 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $2.50 |
| AVG Volume (30 Days) | 22.4K | ★ 1.0M |
| Earning Date | 09-30-2026 | 08-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 89.07 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.33 | $0.14 |
| 52 Week High | $13.00 | $0.49 |
| Indicator | DOGZ | TOVX |
|---|---|---|
| Relative Strength Index (RSI) | 18.61 | 29.84 |
| Support Level | N/A | N/A |
| Resistance Level | $1.41 | $0.25 |
| Average True Range (ATR) | 0.08 | 0.02 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 32.29 | 29.78 |
Dogness (International) Corp designs, manufactures pet products, including leashes and smart products, and lanyards. The company designs, processes, and manufactures fashionable and high-quality leashes, collars, and harnesses to complement cats and dogs appearances, as well as intelligent pet products. The company also provides dyeing services to external customers, as well as pet grooming services. The dyeing service is to utilize the existing production capacity and the pet grooming service is immaterial. Geographically, it generates maximum revenue from Europe and also has a presence in the Mainland China, United States, Europe, Australia, Canada, Central, and South America, Japan, and other Asian countries and regions.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system. Product Candidates includes SYN-004 (ribaxamase) and SYN-020.